INTRODUCTION
Liver transplant (LT) recipients have a higher risk of developing malignancies, particularly skin cancers and lymphoproliferative tumours 1, 2 . The risk of developing solid tumours is less well documented. Retrospective studies have demonstrated conflicting results regarding the risk of colorectal cancer (CRC) development and post-LT survival 1, [3] [4] [5] [6] [7] [8] [9] [10] . According to the European Liver Transplant Register, primary sclerosing cholangitis (PSC) is the primary indication for LT in approximately 5% of all adult recipients 11 and is associated with inflammatory bowel disease (IBD) in up to 70% of patients 12 . In comparison to the general population, patients with PSC-IBD have a 10-fold increased risk of CRC, while patients with PSC alone have a 5-fold increased risk of CRC [12] [13] [14] [15] . Moreover, CRC in this group of patients appears to develop at a younger age and is diagnosed at a more advanced stage compared with the general population, is predominantly localised in the ascending colon and represents one of the leading causes of death 12, 14 .
A recent meta-analysis on 29 selected studies (18,875 patients: 1,732 with PSC, 111 CRC cases), which aimed to analyse the risk of CRC in all post-LT patients indicated that the pooled relative risk (RR) of CRC was 2.59 in all LT recipients (7 studies were included for this analysis) and 1.8 in the non-PSC LT population (calculated on the results of 10 studies) 16 . A subsequent report on 18 studies (69 cases of CRC observed in 1987 PSC patients and 66 of them in the 1017 PSC-IBD patients, with a mean/median post-LT follow up ranging from 3 to 11 years) aiming to analyse the incidence of CRC in PSC and PSC-IBD LT recipients, showed a high incidence rate (IR) in both groups (IR 5.8 and 13.5 cases per 1000 person-years respectively) 17 .
In the present study, we used national data to assess the risk and outcome of CRC after LT.
We therefore analysed: i) the incidence of post LT CRC and ii) whether cancer survival outcomes are comparable to the general population in LT patients with or without ulcerative colitis and with or without PSC by performing a retrospective analysis of prospectively collected national data in the UK.
MATERIALS AND METHODS
This is a national multicentre retrospective cohort study. Data from all adult patients undergoing a LT in 6 out of the 7 Liver Transplant Units of the United Kingdom between January 1 st 1990 and December 31 st 2010 were analysed. National ethical approval, National Health Service Blood and Transplant (NHSBT) approval and National Information Governance Board approval were obtained to perform this study. Prospectively collected liver transplant data was obtained from NHSBT. Retrospective data was obtained from electronic patient records, patient notes and hospital databases. The Yorkshire Cancer Registry, which is the lead UK registry for colorectal cancer, cross matched the datasets against the cancer registry database and provided a list of liver transplant patients with a diagnosis of CRC as well as the survival data on all colorectal cancer patients within the specified dates. Patients were followed from the first recorded liver transplant until death or 31st
December 2012. Those with evidence of colectomy prior or during first transplant were excluded from the analysis.
Statistical analysis
The following populations were considered: (i) all transplanted individuals, (ii) those without either ulcerative colitis (UC) or PSC (iii), those with either UC or PSC and (iv) those with UC only. The incidence of CRC in these populations compared to that in the general population was assessed through Standardised incidence ratios (SIR). Age-and sex-adjusted estimates of the expected number of cases in each population were derived based on the rate of CRC in the UK Characteristics of the whole LT cohort and patients diagnosed with CRC are shown in Table 1 and Table 2 . 677 (8.3%) patients had either UC or PSC. Amongst individuals with CRC, 27 (51.9%) had either PSC or UC. The tumour localisation was equally distributed in the proximal and distal colon. The tumours were moderately differentiated (grade 2) in 76.9% of cases and were predominantly T3 tumours (50% of cases in the whole LT population, 47.6% in the PSC/UC group and 66.7% in patients without PSC/UC, Table 2 ).
CRC incidence in LT population compared to the general population

Whole LT population:
There were a total of 63,609 person years at risk with a median (IQR) follow up time of 6.7 with the rate of CRC in the UK population, the SIR was 10.90 (95% CI=(7.08-16.10)). The probability of developing a CRC after LT in patients with UC appears to be increasing linearly and is shown in Supplementary Figure 2 .
Patient survival from CRC diagnosis
Whole LT population (n=8,115)
Thirty-one (59.6%) patients with CRC died. Median (95% CI) survival from cancer diagnosis was 4.7 (2.1-8.0) years. One, five and ten-year survival rates from CRC diagnosis were 71%, 48% and 31% respectively ( Figure 1A) . The probability of death due to CRC at 1, 5 and 10 years was 17.4%, 17.4% and 23.8% ( Figure 1B) .
Population with UC or PSC (n=677)
There were 27 patients diagnosed with CRC who also had either UC or PSC. Of these, 13 (48.2%) died during follow up. Median survival time was 8.0 years. One, five and ten-year survival rates from CRC diagnosis were 81%, 59% and 47% respectively ( Figure 2 ).
Population without UC or PSC (n=7,438)
There were 25 patients with CRC that did not have either UC or PSC. Of these, 18 (72%) died during follow up. Median survival time was 3.1 (0.7-6.4) years. One and five year survival rates from CRC diagnosis were 60%, 37% respectively ( Figure 3A) . The probability of death due to CRC at 1, 5 and 10 years was 32%, 32% and 46.6% respectively ( Figure 3B ).
Population with UC (n=354)
There were 23 patients in this population with CRC. Of these, 11 (47.8%) died during follow up. Median survival time was 8.0 years (CI couldn't be estimated). One, five and ten-year survival rates from CRC diagnosis were 82%, 61% and 46% respectively (Figure 4 ).
DISCUSSION
Our study has demonstrated significantly increased risk of CRC in the PSC/UC group of transplanted patients (SIR 7.0) but not in the whole LT group (SIR 0.92), when compared with the general population. It has further shown that tumours are frequently diagnosed at an advanced stage, despite increased awareness and vigilance. To the best of our knowledge, we describe in the present study the results from both the largest European LT and LT-PSC/UC cohort published in the literature (8115 and 677 patients respectively). Although solid organ malignancies have been reported to occur in about 11% of LT recipients 21 , and several studies 1, 8, 28-30 report a high incidence of post-LT CRC, we observed no increased incidence in the whole LT population, with a crude incidence rate (95% CI) of 8.2 (6.0- Patients with PSC/UC have been reported to have an increased risk of CRC development [12] [13] [14] [15] , potentially with a greater risk after LT due to a possible contribution of other factors such as the immunosuppressive therapy or a more aggressive course of the IBD after transplant [31] [32] [33] [34] .
Our analysis identified the PSC/UC group as at significantly increased risk for CRC development after LT either when compared to the general population (SIR 7) or the non-PSC/UC LT recipients (SIR 12.3). Moreover, patients with UC showed a risk of CRC development over 10 times higher than the general population (SIR 10.9). These results are similar to those of a recent study on the whole US transplant population 35 where PSC and IBD LT recipients showed an increased CRC risk.
We estimated a SIR of 7, which is higher than the SIR of 5 reported by Boonstra and colleagues 12 of 5.0 in a PSC population not undergoing LT. Comparing these results it is important to consider that these populations are not matched for the time from PSC diagnosis. The CRC risk distribution in PSC/IBD patients increases with time 2 as the duration and the extent of the disease represent the predominant risk factors for tumour development 36, 37 . Therefore the greater SIR after LT could just reflect a longer duration of the underlying disease in this population. Our results have shown a linear increase of probability of developing a CRC after LT in the whole LT population and in patients with UC ( Supplementary Figures 1 and 2) . The LT recipients are also burdened by the possible role of the drug-induced immunosuppression in the carcinogenesis 28, 35, 38 When compared with the general UK population 41 , we report CRC being diagnosed at a more advanced stage with 65% of tumours being T3-T4. We also found that patient survival from CRC diagnosis was less than 50% at 5 years and 31% at 10 years. Over 20% of patients diagnosed with CRC died from cancer-specific causes during the follow-up. Our results demonstrated superior patient survival from CRC diagnosis in the PSC/UC population than in the whole LT population and in patients without PSC/UC ( Figures 1A, 2 and 3A) .
Limitations of the present study include the retrospective nature of data collection that were incomplete for some parameters. The heterogeneity of the different centres' policies regarding post-LT colonoscopy did not allow evaluation of whether a screening protocol might be able to improve earlier diagnosis. However, liver transplant candidates and recipients are likely to have undergone colonoscopy (and possibly polypectomy) more frequently than the general population as part of the pre-LT evaluation or post-LT follow up, and this might have resulted in a reduction of the risk of CRC development. This further strengthens the finding of increased CRC risk in patients transplanted for PSC. In the UK, there is a nationwide screening for CRC development with faecal blood assays every 2 years offered to all men and women aged 60 to 74. Moreover, due to the small number of patients developing a post LT CRC, it was not possible to perform a uni-and multivariate analysis to identify independent risk factors for CRC development.
In conclusion, our results suggest that LT in unselected patients is not associated with an increased risk of CRC development. The PSC/UC LT population showed a significantly increased risk of CRC development (7 times higher than the general population). Considering the proportion of advanced CRC stage at diagnosis and the patient survival, a long-term post LT screening program would be advisable in patients with PSC/UC and an intact colon. In this scenario, prophylactic colectomy could play a role, since it has been demonstrated that PSC patients who had a pre-LT colectomy or don't suffer from UC carry a significantly lower risk of recurrent PSC when compared to patients with UC and no colectomy, which is strongly associated to an increased rate of graft failure and patient death 42 .
